Cardiovascular diseases are the number one killer in the European Union and cost the European community € 196 billion per year. € 106 billion of this budget is spent on health care, including diagnosis and treatment of patients. The rapidly ageing population in the border region creates the expectation that cardiovascular disease will have a strongly increasing negative impact on our society. A large proportion of people with cardiovascular disease shows no serious symptoms during the development of the disease, and is therefore not under treatment. Better and earlier identification of these individuals with an increased health risk is highly desirable. Also, a proper diagnosis for already identified patients is essential to refine the therapy, and to have fewer side effects or complications. ‘TTD’ therefore focuses on the development of a diagnostic kit. This form of personalized health care is seen as the way to more efficient cardiovascular health care, versatile and with fewer additional health damages and costs to the individual and society. These efforts will eventually not only have a positive effect on health care, but also respond to the needs and demands of business and health care providers.